Related Experiment Video
Updated: Nov 17, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Durable response achieved using Pazopanib for germ tumor cells: A case report
Yuta Takezawa1,2, Hiroshi Yaegashi1, Masashi Iijima1
1Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa 920-8641, Japan.
Abstract:
Germ cell tumors with somatic-type malignancy (GCTSTM) are rare, and patients with GCTSTM have extremely poor prognoses with a median survival of nine months. Somatic-type malignancy, which are mainly sarcomas, usually exhibit chemoresistance. The recommended therapy for GCTSTM is radical resection; however, Pazopanib, which is a multityrosine kinase inhibitor, has indicated therapeutic effects for some soft tissue sarcoma components. The current study reports the case of a 21-year-old Asian man who presented with GCTSTM after combined chemotherapy for a primary mediastinal germ cell tumor with multiple lung metastases. Despite the metastases, his disease was stable after continuous administration of Pazopanib for two years and then stopping the medication for four years. To the best of our knowledge, the current report is the first report of a durable response by Pazopanib for GCTSTM, which is a rare outcome.
Insights
Germ cell tumors with somatic-type malignancy (GCTSTM) are rare and aggressive. Pazopanib demonstrated a rare, durable response in a patient with GCTSTM, offering a potential new treatment avenue.
Area of Science:
- Oncology
- Medical Case Reports
Background:
- Germ cell tumors with somatic-type malignancy (GCTSTM) are rare and associated with extremely poor prognoses.
- Somatic-type malignancies, often sarcomas, typically exhibit chemoresistance, complicating treatment strategies.
Purpose of the Study:
- To report a rare case of a durable response to Pazopanib in a patient with GCTSTM.
- To highlight Pazopanib as a potential therapeutic option for GCTSTM.
Main Methods:
- A case study of a 21-year-old male patient with GCTSTM following chemotherapy for a primary mediastinal germ cell tumor.
- Administration of Pazopanib, a multityrosine kinase inhibitor, for two years.
Main Results:
- The patient achieved disease stability despite multiple lung metastases.
- The patient maintained stability for four years after discontinuing Pazopanib.
Conclusions:
- This case represents the first reported durable response to Pazopanib in GCTSTM.
- Pazopanib may offer a novel therapeutic strategy for managing GCTSTM, a condition with limited treatment options.
